Taysha Gene Therapies, Inc. (TSHA): Shareholders' Equity
$246.94M
As of 2025-12-31
$387.27M
As of 2026-06-30
n/m
3-year compound annual growth
-0.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $246.94M | +245.2% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $71.53M | -4.6% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $74.94M | n/m | 2025-02-26, Balance as of period end |
| 2022-12-31 | $949.0K | -99.0% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $95.38M | -62.0% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $251.30M | n/m | 2022-03-31, Balance as of period end |
| 2019-12-31 | -$135.0K | n/a | 2021-03-03, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $246.94M | +245.2% |
| Curis Inc (CRIS) | 2025-12-31 | $5.46M | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $62.53M | +59.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $123.12M | -48.9% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $122.17M | -51.7% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $207.18M | -35.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $43.35M | -43.7% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $567.06M | -27.1% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $38.88M | n/m |
Compare TSHA, CRIS, ACOG, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗